RXi Pharmaceuticals: Making Significant Headway With Pipeline
Edison | Nov 04, 2015 05:58AM ET
Delivering on its self-delivering RNAi platform
Over the past year, Rxi Pharmac (O:RXII) has made significant headway with its pipeline as well as in securing partnerships. Its lead compound RXI-109 is in Phase II in dermatological scarring and is entering the clinic this year in retinal scarring in wet AMD. Phase II dermatology treatment Samcyprone was in-licensed, while a deal was struck with MirImmune for the out-licensing of its proprietary sd-rxRNA technology. We expect the company’s budding pipeline, recently simplified shareholder structure and deal-oriented strategy will continue to garner renewed investor attention and share price momentum. We value RXi at $91m or $1.40 per share.
Portfolio progressing with initiation of key trials
RXi is advancing three projects in clinical programs in the coming months. A Phase I/II trial for RXI-109 for the prevention of subretinal scarring in wet AMD should commence in 2015 on its newly FDA cleared IND. RXI-109’s lead indication of dermal scarring reports six-month data in early 2016 in the ongoing 1402 study, after recently announcing positive results of a three-month read out. We forecast peak sales of $1.5bn for RXI-109 in the dermal scarring market, which includes sales from reconstructive procedures and scar revision surgery, assuming payments are mainly out of pocket. RXi also plans the initiation of a Phase II trial with the recently in-licensed Samcyprone in common warts in the coming months.
Technology platform with out-licensing potential
RXi has developed a 'self-delivering' RNAi platform (sd-rxRNA), which it believes has advantages over conventional RNAi silencing, with the aim of achieving efficient spontaneous cell uptake, potent and long-lasting intracellular activity but lower immune activation. In preclinical studies RXi has demonstrated efficient cellular uptake of sd-rxRNA in tissues such as skin, retina, lung, spinal cord and liver. In March 2014, RXi out-licensed RXi’s sd-rxRNA technology to MirImmune for ex vivo use in developing cell-based cancer immunotherapies, signifying validation of RXI’s technology platform and paving the way for similar future agreements.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.